Dr. Agarwal On Androgen Receptor Inhibitors For Prostate Cancer

Dr. Agarwal on Androgen Receptor Inhibitors for Prostate Cancer

Dr. Agarwal on Potential Agents for Metastatic Hormone-Sensitive Prostate Cancer

Choosing the correct PARP inhibitor for prostate cancer

Dr. Agarwal on Treatment for Newly Diagnosed Prostate Cancer

Dr. Agarwal on Drug Development in Metastatic Castration-Sensitive Prostate Cancer

Dr. Aggarwal on Androgen Deprivation Therapy for Prostate Cancer

Dr. George on Investigational Agents Downstream of the Androgen Receptor in Prostate Cancer

Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate Cancer

Dr. Aggarwal on the Future of ADT for Patients With Prostate Cancer

Dr. Higano on the Toxicity of Androgen Receptor Inhibitors in CRPC

Androgen Deprivation Therapy and Prostate Cancer

University of California Television (UCTV)

Tomasz Beer, MD, FACP, reviews updates concerning androgen receptor inhibitors in nmCRPC

Metastatic Prostate Cancer: Androgen Receptor Biology

Androgen Receptor and Castration-Resistant Prostate Cancer

Dr. Agarwal on the COSMIC-021 Trial Design in Castration-Resistant Prostate Cancer

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

Dr Choudhury on Survival Advantages With AR Pathway Inhibitors in mHSPC

Androgen Receptor-Targeted Ttherapies in Advanced Prostate Cancer

Androgen receptor inhibitors

Science in Motion

The Management of Prostate Cancer with Androgen Receptors

Grand Rounds in Urology